What are the treatment options for a 20‑year‑old woman with severe, recalcitrant hidradenitis suppurativa (Hurley stage III)?

Treatment of Severe Recalcitrant Hidradenitis Suppurativa in a 20-Year-Old Female

For a 20-year-old woman with Hurley Stage III hidradenitis suppurativa, initiate adalimumab 160 mg subcutaneously at week 0,80 mg at week 2, then 40 mg weekly (not every other week) starting at week 4, while simultaneously bridging with oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks, and plan for radical wide surgical excision of all involved tissue as the only intervention achieving lasting cure. 1

Immediate Medical Therapy

First-Line Biologic Treatment

• Adalimumab is the sole FDA-approved biologic for moderate-to-severe HS in patients ≥12 years of age, making it appropriate for this 20-year-old patient. 1, 2
• Dosing must be 40 mg weekly—the every-other-week schedule used in other conditions is completely ineffective for Hurley Stage III disease. 1
• Expected HiSCR response rates (≥50% reduction in abscess/nodule count with no increase in abscesses or draining fistulas) are 42–59% at week 12. 1
• Assess response at week 12 using HiSCR, pain VAS, and inflammatory lesion count; if inadequate response persists after 16 weeks, escalate to second-line biologics. 1

Bridge Antibiotic Therapy

• While awaiting biologic approval or during the first weeks of adalimumab, prescribe oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks to control acute inflammation. 1
• This combination achieves response rates of 71–93% and is far superior to tetracycline monotherapy. 1, 3
• After completing the 10–12 week course, incorporate treatment breaks to assess ongoing need and limit antimicrobial resistance risk. 1

Acute Symptom Relief

• Inject intralesional triamcinolone 10 mg/mL (0.2–2 mL per lesion) into acutely inflamed nodules for rapid symptom relief within 24 hours. 1
• Provide NSAID analgesia for pain management throughout therapy. 1
• Apply appropriate wound dressings tailored to drainage volume and lesion location. 1

Surgical Management—The Only Curative Option

Definitive Surgical Approach

• Radical wide local excision of all involved tissue, including sinus tracts and scarring, is the only intervention achieving lasting cure, with non-recurrence rates of approximately 81% after wide excision. 1
• The width of excision directly influences therapeutic outcome—wider margins improve cure rates. 1
• Combine adalimumab with surgery rather than using adalimumab alone, as concurrent medical-surgical management yields superior clinical effectiveness. 1

Reconstruction Options

• Choose wound-closure method based on disease extent: secondary-intention healing (preferred for extensive disease), split-thickness skin grafts, or local flaps such as thoracodorsal-artery-perforator (TDAP) flaps. 1

Second-Line Biologic Options if Adalimumab Fails

• If inadequate response after 16 weeks of adalimumab, consider infliximab 5 mg/kg at weeks 0,2,6, then every 2 months. 1
• Secukinumab produces response rates of 64.5–71.4% in adalimumab-failure patients at 16–52 weeks. 1
• Ustekinumab represents an alternative pathway targeting different cytokines than TNF-alpha. 1

Mandatory Adjunctive Measures

Lifestyle Modifications

• Refer for smoking cessation immediately—tobacco use confers an odds ratio of 36 for increased HS severity and worsens treatment outcomes. 1
• Refer for weight-management counseling—obesity carries an odds ratio of 33 for poor antibiotic response and higher surgical complication rates. 1

Comorbidity Screening

• Screen for depression and anxiety with validated tools—HS patients have markedly higher suicide rates than the general population. 1
• Measure blood pressure, lipid profile, and HbA1c—cardiovascular mortality is nearly doubled and diabetes prevalence reaches approximately 30% in HS cohorts. 1
• Review gastrointestinal symptoms to identify coexisting inflammatory bowel disease, particularly Crohn's disease. 1
• Examine chronic perineal and buttock lesions for squamous cell carcinoma, the most frequent malignancy at these sites. 1

Treatment Monitoring Protocol

• Document baseline pain (VAS) and lesion count before initiating therapy. 1
• Reassess at 12 weeks using pain VAS, inflammatory lesion count, HiSCR, and Dermatology Life Quality Index (DLQI). 1
• Do not extend antibiotic therapy beyond 12 weeks without formal reassessment, as prolonged use increases resistance without proven benefit. 1

Critical Pitfalls to Avoid

• Do not rely on antibiotics alone for Hurley Stage III disease—non-surgical approaches rarely achieve lasting cure. 1
• Do not use topical clindamycin or oral tetracyclines as monotherapy for Stage III—they have minimal effect on deep lesions and sinus tracts. 1
• Do not prescribe adalimumab 40 mg every other week—weekly dosing is mandatory for Stage III disease. 1
• Do not prescribe isotretinoin, etanercept, or cryotherapy for moderate-to-severe HS—these modalities are ineffective. 1

Disease Counseling

• Hurley Stage III is characterized by multiple/extensive sinus tracts and scarring with persistent purulent discharge from numerous draining tracts. 1
• Patients typically experience chronic purulent discharge, severe pain, malodor, and a mean DLQI of 8.9, reflecting substantial morbidity. 1
• Chronic disease can lead to fibrosis, contractures, fistula formation (urinary, bladder, rectal), lymphedema, anemia, and reduced mobility. 1